Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06724653
Recruiting Not applicable

Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

NCT06724653 · tracked via the Priya Life Science South Korea tracker
Sponsor
Chungnam National University Hospital
Phase
Not applicable
Started
2025-03-06
Last updated
2026-03-27

Condition(s) studied

Heart FailureEjection FractionRecovery of Function

Investigational drug(s) / intervention(s)

RAS blocker tapering groupBeta blocker tapering out

RAS blocker tapering group: RAS blocker tapering out

Beta blocker tapering out: Beta blocker tapering out group

Study summary

Study start date is on Nov 27th 2024.

A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * initial echocardiogram ejection fraction less than 40% * follow up echocardiogram ejection fraction over 50% and LVEDD index normal range * NTprobnp criteria 1. eGFR ≥60 ; less 440 2. eGFR 45-59: less 980 3. eGFR 30-44; less 1220 4. eGFR \< 30 : less 5300 5. in HD; no criteria for NTproBNP * on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor) Exclusion Criteria: 1. under age 18 year 2. uncontrolled BP ( over 150/90) 3. coronary revascularization within 6 months 4. significant valve disease 5. arrhythmia requiring rate control 6. CKD with albuminuria ( over 30mg/g) 7. Pregnancy

Primary outcome measure(s)

  • Heart failure relapse — From enrollment to the end of treatment at 18 months
    LVEF 10% drop, EF less than 50 %, LVIDd/BSA 10% increase, over 33mm/m\^2

Trial sites (2)

FacilityCityRegionStatus
Jeonbuk national university hospital Jeonju Jeollabuk-do Recruiting
Chungnam national university hospital Daejeon Republic of Korea Recruiting

More Chungnam National University Hospital trials in South Korea

Analysis of Cerebrospinal Fluid Dynamics in Normal Pressure Hydrocephalus Recruiting
Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients Enrolling by invitation
Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics Recruiting
Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes Enrolling by invitation
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer Recruiting

Other trials for the same condition

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure Recruiting
Personalized Health Coaching for Patients With HF Recruiting
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study Recruiting
Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06724653 on ClinicalTrials.gov ↗ ← All trials in South Korea